Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)

Volume 15, 2 Issues, 2017

Download PDF Flyer

Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?

Anti-Infective Agents, 3(2): 109-133.

Author(s): Pere Domingo, Francesc Vidal and Joan Carles Domingo.

Affiliation: Infectious Diseases Unit,Department of Internal Medicine, Hospital de la Santa, Creu i Sant Pau Av., Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain.


Highly active antiretroviral therapy (HAART) has dramatically decreased the morbidity and mortality related with HIV-1 infection. However, at the same time, the impossibility of eradicating the infection has made lifelong therapy with antiretrovirals necessary. This has caused the emergence of multiple side effects, including previously unseen and unexpected adverse drug reactions. In addition, the combination of different classes of drugs sometimes sharing common toxic mechanisms has made additive toxicity an increasing event. The purpose of the present work is to review the molecular mechanisms of action of the different antiretrovirals now used in clinical practice, and through these to gain insight into the potential mechanisms of antiretroviral drugsassociated toxicity. Two basic mechanisms of toxicity have been described associated with antiretroviral drugs; i.e. mitochondrial toxicity associated with the use of nucleoside reverse transcriptase inhibitors (NRTIs), and the metabolic toxicities associated with HIV-1 protease inhibitors. Both types of mechanisms eventually cause multiple clinical manifestations, and among them, the most important are the fat redistribution syndromes associated with HIV-1 infection and HAART. On the other hand, the growing knowledge about the pathogenic mechanisms of antiretroviral drugs-associated toxicities has promoted advances in the therapeutic approach, and overall, the design of new and promising antiretroviral drugs that may avoid some of the prior deleterious consequences of antiretroviral drug administration. In the context of long-term antiretroviral treatment for longterm surviving HIV-1 infected patients, this may be the best hope for the still growing number of infected patients worldwide.


drugs-associated, long-term toxicity, highly active antiretroviral therapy, antiretrovirals, hiv-1 infection.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 3
Issue Number: 2
First Page: 109
Last Page: 133
Page Count: 25
DOI: 10.2174/1568012043354053
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science